References
- Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ146(4), 473–481 (1992).
- Drummond M, Sorenson C. Nasty or nice? A perspective on the use of health technology assessment in the United Kingdom. Value Health12(Suppl. 2), S8–S13 (2009).
- Jacobs P, Roos NP. Standard cost lists for healthcare in Canada. Issues in validity and inter-provincial consolidation. Pharmacoeconomics15(6), 551–560 (1999).
- Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA298(2), 221–224 (2007).
- Wilensky GR. The policies and politics of creating a comparative clinical effectiveness research center. Health Aff.28(4), w719–w729 (2009).
- Sheldon TA, Cullum N, Dawson D et al. What’s the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients’ notes, and interviews. BMJ329(7473), 999 (2004).
- Eddama O, Coast J. Use of economic evaluation in local health care decision-making in England: a qualitative investigation. Health Policy89(3), 261–270 (2009).
- Hoffman C, von der Schulenburg G. The influence of economic evaluation studies on decision making: a European study. Health Policy52, 179–192 (2000).
- Hutton J, Brown RE. Use of economic evaluation in decision making: what needs to change? Value Health5(2), 65–66 (2002).
- Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications. BMC Health Serv. Res.8, 270 (2008).
- Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health12(Suppl. 1), S10–S15 (2009).
- Sheridan C. Vaccine market boosters. Nat. Biotechnol.27(6), 499–501 (2009).
- Jacobs P, Yim R, Ohinmaa A et al.Economics of Childhood Immunizations in Canada: Data Book. Institute of Health Economics, Edmonton, Alberta, Canada (2007).
- Kresse H, Rovini H. Influenza vaccine market dynamics. Nat. Rev. Drug Discov.8(11), 841–842 (2009).
- Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect. Dis.8(11), 727–733 (2008).
- Lieu TA, Cochi SL, Black SB et al. Cost–effectiveness of a routine varicella vaccination program for US children. JAMA271(5), 375–381 (1994).
- Jacobs P, Ohinmaa A. A comparison of the use of economics in vaccine expert reviews. Vaccine28(16), 2841–2845 (2010).
- Lilly MB, Laporte A, Coyte PC. Do they care too much to work? The influence of caregiving intensity on the labour force participation of unpaid caregivers in Canada. J. Health Econ.29(6), 895–903 (2010).
- Advisory Committee on Immunization Practices. Preventing pneumoccal disease among infants and young children: recommendations. MMWR Recomm. Rep.49(RR09), 1–38 (2000).
- Williams A. Welfare economics and health status measurement. In: Health, Economics, and Health Economics. van der Gaag J, Perlman M (Ed.). North-Holland Publishing Company, Amsterdam, The Netherlands, 271–281 (1981).
- Nohynek H. The Finnish decision-making process to recommend a new vaccine. J. Public Health16, 275–280 (2008).
- Erickson LJ, De WP, Farand L. An analytical framework for immunization programs in Canada. Vaccine23(19), 2470–2476 (2005).
- World Health Organization. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. Vaccine (11), 2356–2359 (2010).
Websites
- Pharmacoeconomic guidelines around the world www.ispor.org/PEguidelines/index.asp
- Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada 3rd edition. Canadian Agency for Drugs and Technologies in Health, Ottowa, Canada (2006) http://cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf
- ACIP: guidance for health economics studies www.cdc.gov/vaccines/recs/acip/economic-studies.htm
- National Institute for Health and Clinical Excellence: appraising life-extending, end of life treatments www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf
- Appraising the value of innovation and other benefits. National Institute for Clinical Excellence London, England (2009) www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf
- Vaccine european new integrated collaboration effort http://venice.cineca.org/vaccines.html